A new poisson and Bayesian-based method to assign risk and causality in patients with suspected hepatic adverse drug reactions: A report of two new cases of ticlopidine-induced hepatotoxicity

Drug Safety

Volumn 25, Issue 10, 2002, Pages 735-750

  Zapater, Pedro ^a,b,c   Such, José ^a,b   Pérez Mateo, Miguel ^a,b   Horga, José Francisco ^a,b  

^a University General Hospital of Alicante   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PLACEBO; TICLOPIDINE;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BAYES THEOREM; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INCIDENCE; INCUBATION TIME; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MEDLINE; POISSON DISTRIBUTION; POSTMARKETING SURVEILLANCE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; REMISSION; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL MODEL;

EID: 0036360981     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225100-00006     Document Type: Article

References (62)

1. Principles of therapeutics
2. Reporting drug side effects: Signals and noise
3. Controversies in adverse drug reaction reporting
4. Drug discovery and development
5. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis
6. General aspects of drug-induced liver disease
7. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of Central Massachusetts
8. Ticlopidine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease status
9. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke
10. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study
11. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
12. Ticlopidina y reacciones adversas hepáticas. Datos recogidos por el sistema Español de farmacovigilancia
13. Lètere cholestatique associé a la prise de ticlopidine: A propose de deux premier cas
14. Hèpatotoxicitè des medicaments. I le mise à jour du fichier bibliographique des atteintes hèpatiques et des mèdicaments responsables
15. Ticlopidine-induced cholestatic hepatitis. Report of three cases and review of the literature
16. Hepatitis colestásica por ticlopidina. Presentación de un nuevo caso
17. Hepatotoxicity due to ticlopidine
18. False-positives in spontaneous reporting: Should we worry about them?
19. Diagnosis and causality assessment of drug-induced hepatic injury
20. Estimation of the numerator in spontaneous reporting
21. Antecedent liver disease and drug toxicity
22. Enhanced differential diagnosis of anticonvulsant hypersensitivity reactions by an integrated bayesian and biochemical approach
23. Letère cholestatique et agranulocytose dus à la ticlopidine
24. Ticlopidine: Atteintes sanguines et hepatiques?
25. Hépatite cholestiatique: Role vraisemblable de la ticlopidine
26. Nyffeneger: Epatosteatosi colestatica di probabile origine iatrogena
27. Changes in plasma lipids and abnormal lipoproteins in a patient with drug-induced cholestatic hepatitis
28. Ittero colestatico da ticiopidina
29. Hèpatite a la ticiopidine: Un nouveau cas
30. Ticlopidine-induced cholestatic jaundice
31. Ticlopidine-induced prolonged cholestasis
32. Ictericia colestásica secundaria a ticlopidina
33. Severe cholestasis associated with ticlopidine
34. More ticlopidine-induced cholestatic jaundice
35. Ictère cholestatique sur ticlopidine: Un nouveau cas
36. Ticlopidine-induced chronic cholestasic hepatitis: A case report
37. Ticlopidine-induced cholestasis: Report of two cases and experimental evidence of the drugs adverse effect in isolated perfused rat liver
38. Probable ticlopidine induced cholestatic hepatitis
39. Ticlopidine-induced granulomatous hepatitis
40. Cholestatic hepatitis: Ticlopidine suspected
41. Ticlopidine induced prolonged cholestasis
42. Hepatitis colestática por ticlopidina
43. Hepatoxicidade pela ticlopidina
44. Hepatitis colestasica y anemia por ticlopidina
45. Colestasis asociada a ticlopidina
46. Hepatitis colestásica asociada a ticlopidina
47. Ticlopidine-induced cholestatic jaundice
48. Due casi di colestasi acuta da ticlopidina
49. Hepatitis tóxica por ticlopidina. Tres nuevos casos
50. Hepatitis colestásica por ticlopidina: Presentación de un nuevo caso
51. Liver injury with the use of ticlopidine
52. Ticlopidine-induced acute cholestatic hepatitis
53. Cholestatic hepatitis due to ticlopidine: Clinical and histological recovery after drug withdrawal. Case report and review of the literature
54. Ticlopidine-induced cholestasis
55. Delayed-onset ticlopidine-induced cholestatic jaundice
56. Ticlopidine-induced prolonged cholestasis: A case report
57. Liver test abnormalities
58. Anticonvulsant and anti-parkinsonian agents
59. Effect of deprenyl on the progression of disability in early Parkinson's disease
60. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease
61. Evaluation of abnormal liver-enzyme results in asymptomatic patients